Drugs / OTENABANT
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01517100 | Jan 2012 → Oct 2014 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1 | NCT00706537 | Jul → Nov 2008 | metabolic dysfunction-associated steatohepatitis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00645021 | Apr → Oct 2008 | liver disorder, obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00644839 | Apr → Jul 2008 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00645216 | Jun → Oct 2007 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00472836 | Jun 2007 → Oct 2008 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00645463 | Mar → Jun 2007 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00134199 | Mar → Nov 2005 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00396448 | Feb 2007 → Feb 2009 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00391196 | Nov 2006 → Dec 2008 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00375401 | Oct 2006 → Jan 2009 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00483171 Comparator | Jan 2008 → Jan 2009 | obesity disorder | Pfizer | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTENABANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL562668 ↗ |
| Known as | CP-945,598 | “CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity.” NCT00706537 ↗ |
| Known as | CP-945598-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL562668 ↗ |
| Known as | Otenabant hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL562668 ↗ |
| Known as | OTENABANT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL562668 ↗ |
| Action | Inhibit | “Cannabinoid-1 (CB1) receptor antagonist” NCT00706537 ↗1“Cannabinoid CB1 receptor antagonist” CHEMBL562668 ↗ |
| Modality | Small molecule | — CHEMBL562668 ↗ |
| Route | Oral | “multiple oral dose administration” NCT00706537 ↗ |
| Target | CNR1 | “Cannabinoid CB1 receptor antagonist” CHEMBL562668 ↗ |